Presenting on the above topic is Dr Haiyan Jiang, Director, Preclinical and Clinical Research, Biogen Idec Hemophilia, United States. She will be speaking at Pharma Trials World Asia 2012, part of a series of conferences at the 5th Annual BioPharma Asia Convention 2012.
Dr Haiyan Jiang is Director of Preclinical and Clinical Research at Biogen Idec Hemophilia, where she co-leads the pipeline research of novel therapeutics and oversees the preclinical development for Hemophilia. She is also responsible for the clinical pharmacology in the ongoing long-acting rFIXFc and rFVIIIFc pivotal trials. Prior to joining Biogen Idec, she was Deputy Director of Pharmacology/Hematology at Bayer HealthCare LLC in Berkeley, California, where she was responsible for the research and preclinical pharmacology of pro-coagulation protein therapeutics. Before that she worked on preclinical and clinical research of Adeno-associated viral vector (AAV) mediated gene therapy for Hemophilia A and B. Dr. Jiang received her PhD in Oncology from University of Wisconsin, Madison and had her postdoctoral training at University of California, San Francisco. She is currently a member of a number of professional societies and review committees. She has also published extensively on research and preclinical pharmacology on novel therapies for Hemophilia.
She will be talking about the below topics:
Developing an innovative preclinical model to drive R&D productivity
1. Recognising the pivotal role of preclinical studies for the successful translation of research to clinical in developing novel therapeutics for Hemophilia
2. Defining an innovative preclinical model to accelerate drug development in Asia
3. Assessing various opportunities and challenges in preclinical development for specialized medicine in Asia
She will also be participating in the following panel discussion:
Panel Discussion: Assessing Asia's competitiveness and growth opportunities in conducting preclinical trials
1. Evaluating changes in the preclinical scene in Asia in the past five years
2. Challenges in preserving the value of preclinical studies for sustainability in Asia's emerging markets
3. Developing the future direction in preclinical and R&D policy strategies for the potential increase in preclinical trials